Skip to Content

'
John C. Araujo, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit 1374
Houston, TX 77030
Room Number: CPB7.3466
Phone: 713-563-7203
Fax: 713-745-1625

Education & Training

Degree-Granting Education

2000 Stritch School of Medicine Loyola University Chicago, Maywood, IL, MD, Medicine
1996 Georgetown University School of Medicine, Washington, DC, PHD, Microbiology and Immunology
1991 Fairfield University, Fairfield, CT, BS, Biology

Postgraduate Training

7/2003-6/2006 Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2001-6/2003 Clinical Residency, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH
7/2000-6/2001 Clinical Internship, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH

Board Certifications

10/2006 American Board of Internal Medicine-Medical Oncology
8/2003 American Board of Internal Medicine-Internal Medicine

Experience/Service

Academic Appointments

Instructor, Emergency Department, Darmouth Hitchcock Medical Center, Lebanon, NH, 10/2002-6/2003

Other Appointments/Responsibilities

Reviewer for Medical Oncology, American Board of Internal Medicine, Houston, TX, 11/2007-present

Institutional Committee Activities

Committee Member, Faculty Senate, 2014-present
Committee Member, Quality Officer, 2013-present
Committee Member, Council of Committee Chairs, 3/2008-present
Vice Chairman, Pharmacy and Therapeutics Committee, 2/2008-8/2008
Committee Member, Department Protocol Review, 11/2007-present

Honors and Awards

2003 Amyloidosis and MGUS Paraproteinemias, Dartmouth Hitchcock Medical Center
2003 Plumbism Secondary to Herbal Medicinal Ingestion, Dartmouth Hitchcock Medical Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. e-Pub 3/7/2016. PMID: 26951312.
2. Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE, Swanston NM, Fox P, Macapinlac HA, Rohren EM. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med. e-Pub 1/30/2016. PMID: 26828141.
3. Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging 43(1):8-20, 1/2016. e-Pub 9/29/2015. PMID: 26416392.
4. Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med 56(8):1177-84, 8/2015. e-Pub 6/11/2015. PMID: 26069307.
5. Bilen, MA, Johnson MM, Mathew P, Pagliaro L, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 1/2015.
6. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. e-Pub 2/2014. PMID: 24522479.
7. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. e-Pub 1/2014. PMID: 24473064.
8. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14(13):1307-16, 12/2013. e-Pub 11/8/2013. PMID: 24211163.
9. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma. Am J Clin Oncol 36(5):450-4, 10/2013. e-Pub 6/2012. PMID: 22706175.
10. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19(13):3621-30, 7/2013. e-Pub 5/2013. PMCID: PMC3699964.
11. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate 73(9):979-85, 6/2013. e-Pub 1/31/2013. PMID: 23371521.
12. Ng L, Heck W, Lavsa S, Crowther D, Atkinson B, Xiao L, Araujo J. The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T. Cancers 5(2):511-18, 5/2013.
13. Eser PO, Vanden Heuvel JP, Araujo J, Thompson JT. Marine-and plant-derived w-3 fatty acids differentially regulate prostate cancer cell proliferation. Molecular and Clin Oncol 76(1):444-452, 2/2013. PMCID: PMCPMC3916163.
14. Araujo JC, Trudel GC, Paliwal P. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel. Cancer Manag Res 6(6):25-30, 2013. e-Pub 3/2013. PMCID: PMC3601649.
15. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. Eur Urology 62(6):1013-9, 12/2012. PMID: 22771265.
16. Ameri H, Araujo JC, Gombos DS. Leuprolide monotherapy for choroidal metastasis from prostate adenocarcinoma. Arch Ophthalmol 130(9):1225-6, 9/2012. PMID: 22965610.
17. Araujo, JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 118(1):63-71, 1/2012. NIHMSID: NIHMS494060.
18. Roychowdhury S, Lyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 111:111ra121, 11/2011. PMID: 22133722.
19. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 6/2011. PMCID: PMCPMC3883511.
20. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-lee LY, Galick GE, Lin SH. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29(22):3196-207, 6/2010. PMID: 20228840.
21. Araujo J, Logothetis C. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev, 3/2010. PMID: 20226597.
22. Araujo JC, Poblenz A, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol & Therapy 8(22):2153-59, 11/2009. PMID: 19855158.
23. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008.
24. Araujo J, Logothetis C. Targeting Src signaling in metastatic bone disease. Int J Cancer 124(1):1-6, 1/2009. PMID: 18942061.
25. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68(9):3323-33, 3/2008. PMID: 18451159.

Abstracts

1. Corn P, Tu S, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncology, 2015 ASCO Annual Meeting 33 (#5010), 5/2015.
2. Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, Le O, Logothetis CJ, Aparicio A. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer 33 (#TPS5075), 5/2015.
3. Maity SN, Wu G, Lu JF, Hoang A, Landesman Y, McCauley D, Carlson R, Rashal T, Shacham S, Broom BM, Baggerly KA, Aparicio A, Efstathiou E, Araujo JC, Logothetis CJ. Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth. J Clin Oncology 33 (#277), 2015.
4. Elba Etchebehere, John C. Araujo, Denai Milton, Patricia S Fox, Nancy Swanston, Homer A. Macapinlac, Eric Rohren. Skeletal tumor burden on baseline 18F-fluoride PET/CT to predict bone marrow failure after radium-223. J Clin Oncol 33:11012, 2015.
5. De Bono JS, Pezaro CJ, Gillessen S, Shore ND, Nordquist LT, Efstathiou E, Araujo JC, Berry WR, Liu G, Vogelzang NJ, Omlin AG, Schotzinger RJ, Eisner JR, Moore WR. The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC. J Clin Oncology 33 (#187), 2015.
6. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SW, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol (#e16046), 6/2014.
7. Corn PG, Tu SM, Zurita AJ, Araujo JC, Pagliaro LC, Logothetis CJ, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32 (#148), 5/2014.
8. Moore WR, Maity SN, Eisner JR, Garvey EP, Hoekstra WJ, Titus WA, Logothetis CJ, Araujo JC, Efstathiou E, Schotzinger RJ. The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. J Clin Oncol 32 (#158), 5/2014.
9. Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu SM, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in men with hormon-naive metastatic prostate cancer (HN-MPCa). ESMO (#7175), 4/2014.
10. Corn PG, Varkaris A, Tapia EM, Araujo CJ, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol (#58), 6/2013.
11. Dayyani F, Varkaris A, Araujo JC, Song JH, Trudel GC, Logothetis C, Gallick GE. Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. J Clin Oncol 31 (#166), 6/2013.
12. Araujo JC, Trudel GC, Saad F, Armstrong AJ, YU EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Malveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, DeBono JS, Paliwal P, Durham S, cheng S, Logothetis C. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol (#LBA8), 2/2013.
13. Dayyani F, Gallick GE, Thompson JT, Trudel GC, Logothetis C, Araujo JC. Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC). J Clin Oncol 28(15S):382s (#4665), 6/2010.
14. Dayyani F, Gallick GE, Trudel GC, Logothetis C, Araujo JC. Decline in bone markers and response to combination therapy with dasatinib and docetaxel in patients with castration-resistant progressive prostate cancer (CRPC). Genitourinary Cancers Symposium Proceedings (#136), 2/2010.
15. Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with castration-resistance progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 27(15S):249s (#5061), 2/2009.
16. Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick G, Trudel GC, Paliwal P, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer: analysis of Study CA180-086. Eur J Cancer Suppl 7:415S (#7028), 2009.
17. Araujo JC, Jonasch E, Tannir N, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26(15S):276s (#5106), 5/2008.
18. Jonasch E, Woods, CG, Matin S, Tamboli P, Do K, Pagliaro C, Aparicio A, Araujo J, Tannir NM. Presurgical bevacizumab in patients with metastatic lear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s (#5104), 5/2008.
19. Zurita AJ, Ward JF, Araujo JC, Pettaway Ca, Pisters LL, Dieringer P, Troncoso P, Logothetis CJ. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 26(15S):271s (#16004), 5/2008.
20. ER Plimack, E Jonasch, BN Bekele, LA Smith, JC Araujo, NM Tannir. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study. J Clin Oncol 26(15S):277s (#5112), 5/2008.
21. Aparicio AM, Lin AM, Araujo JC, Logothetis JC, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer. J Clin Oncol 26(15S):271s (#16000), 5/2008.

Grant & Contract Support

Title: MD Anderson Cancer Center Prostate Cancer SPORE – Project 2: Targeting Tumor Microenvironment-induced Therapy Resistance in Prostate Cancer Bone Metastasis
Funding Source: NIH/NCI
Role: Clinical Co-Leader
Principal Investigator: Christopher J. Logothetis
Duration: 4/1/2016 - 3/31/2021
 
Title: M. D. Anderson Cancer Center Prostate SPORE
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: Christopher Logothetis
Duration: 9/2/2009 - 8/31/2014
 
Title: Role of Fibroblast Growth Factor 9 in Prostate Cancer Bone Metastasis
Funding Source: U T M. D. Anderson Cancer Center
Role: Principal Investigator-MDACC
Duration: 10/1/2006 - 10/1/2007
 
Funding Source: U T M. D. Anderson Cancer Center
Role: Postdoctoral Fellow
Principal Investigator: Waun Ki Hong, MD
Duration: 1/1/2005 - 6/30/2006

Last updated: 7/6/2016